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Today, insulin analogs are used in millions of diabetic patients. Insulin analogs have been
developed to achievemore physiological insulin replacement in terms of time-course of the
effect. Modiﬁcations in the amino acid sequence of the insulin molecule change the phar-
macokinetics and pharmacodynamics of the analogs in respect to human insulin. However,
these changes can alsomodify themolecular and biological effects of the analogs.The rapid-
acting insulin analogs, lispro, aspart, and glulisine, have a rapid onset and shorter duration
of action. The long-acting insulin analogs glargine and detemir have a protracted duration
of action and a relatively smooth serum concentration proﬁle. Insulin and its analogs may
function as growth factors and therefore have a theoretical potential to promote tumor
proliferation. A major question is whether analogs have an increased mitogenic activity in
respect to insulin. These ligands can promote cell proliferation through many mechanisms
like the prolonged stimulation of the insulin receptor, stimulation of the IGF-1 receptor (IGF-
1R), prevalent activation of the extracellular-signaling-regulated kinase (ERK) rather than the
protein kinase B (PKB/AKT) intracellular post-receptor pathways. Studies on in vitro models
indicate that short-acting analogs elicit molecular and biological effects that are similar to
those of insulin. In contrast, long-acting analogs behave differently. Although not all data
are homogeneous, both glargine and detemir have been found to have a decreased bind-
ing to receptors for insulin but an increased binding to IGF-1R, a prevalent activation of the
ERK pathway, and an increased mitogenic effect in respect to insulin. Recent retrospective
epidemiological clinical studies have suggested that treatment with long-acting analogs
(speciﬁcally glargine) may increase the relative risk for cancer. Results are controversial
and methodologically weak. Therefore prospective clinical studies are needed to evaluate
the possible tumor growth-promoting effects of these insulin analogs.
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INTRODUCTION
In addition to its typical metabolic effects, insulin is also a growth
factor as shown by both in vitro and in vivo evidence. Insulin
mitogenic effect was ﬁrst believed to occur only at high concen-
trations via the IGF-1 receptor (IGF-1R), but it was later demon-
strated to occur also at lower concentrations via its own receptor
(Ish-Shalom et al., 1997). The mitogenic effects of hyperinsuline-
mia may be clinically relevant when considering the large num-
ber of subjects with endogenous compensatory hyperinsulinemia
induced by insulin resistance or exogenous hyperinsulinemia due
to the insulin treatment in diabetic patients (Vigneri et al., 2006,
2009). These concerns also apply to insulin analogs that have a
molecular structure similar to that of insulin and interact with
the insulin receptor, eliciting metabolic effects similar to those of
insulin but either faster ormoreprolonged inorder to bettermimic
the physiological condition and obtain an improved metabolic
control (Vajo et al., 2001; Hirsch, 2005). Because of differences
in the structure, insulin analogs may interact with receptors for
insulin (IR) or IGF-1R in a slightly different way, activating meta-
bolic and mitogenic pathways somewhat differently than native
insulin (Drejer, 1992; Slieker et al., 1997; Ciaraldi et al., 2001; Vajo
et al., 2001; Rakatzi et al., 2003; Jensen and De Meyts, 2009). For
instance B10Asp, a single amino acid-substituted insulin analog
that has increased afﬁnity for both IR and IGF-1R as well as
longer residence on the IR, was documented to have a poten-
tial oncologic risk (Hansen et al., 1996; Milazzo et al., 1997; Berti
et al., 1998; Kurtzhals et al., 2000). Its biological characteristics
were associated with increased occurrence of mammary tumors
in B10Asp-treated female rats (Dideriksen et al., 1992; Ebeling
et al., 1996). A 52-week exposure of rats to supraphysiological
B10Asp concentrations revealed a dose-dependent increase in the
occurrence of mammary tumors in female Sprague-Dawley rats
(Drejer, 1992). Because of this concern all insulin analogs have
been tested for their mitogenic potential during pre-clinical and
clinical experimentation. Available data, however, are incomplete
and the procedures used for checking B10Asp carcinogenic effect
have not been repeated for all analogs (Smith and Gale, 2009).
In the last two decades accumulating evidences have established
that insulin receptors are usually expressed at high levels in cancer
cells, both in vitro and in vivo, and that these receptors directly
mediate the biological effects of insulin, bothmetabolic andmito-
genic (Papa et al., 1990; Frasca et al., 1999; Sciacca et al., 1999;
Vella et al., 2002). Moreover, cells can express the IR in two iso-
forms (IR-A and IR-B), generated by alternative splicing of the
insulin receptor gene that either includes or excludes 12 amino
acid residues encoded by a small exon (exon 11) at the carboxyl
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terminus of the IR α-subunit. The two IR isoforms are character-
ized by subtle differences in binding and signaling and by a major
difference in IGF-2 binding: IR-A, but not IR-B, binds IGF-2 with
high afﬁnity and behaves as a second physiological receptor for
this growth factor (Frasca et al., 1999). The two IR isoforms have
slightly different biological characteristics (Mosthaf et al., 1990;
Belﬁore et al., 2009).
In each cell the relative abundance of IR isoforms is regulated by
tissue-speciﬁc and differentiation-related factors that are mostly
unknown (Belﬁore et al., 2009). Moreover, it was observed that
IR splicing is altered in cancer cells, causing aberrant (increased)
expression of IR-A that was found to be the predominant IR iso-
form in a variety of carcinomas, including carcinomas of the
breast, thyroid, ovarian, colon, lung (Frasca et al., 1999; Sciacca
et al., 1999; Kalli et al., 2002; Vella et al., 2002). IR-A overexpres-
sion is not limited to malignancies derived from epithelial cells
but also from mesenchymal cells like osteosarcoma (Avnet et al.,
2009).
Given the high degree of homology, half-receptors (composed
on one α- and one β-subunits) of the two IR isoforms can het-
erodimerize, leading to the formation of the hybrid IR-A/IR-B
insulin receptors (Blanquart et al., 2008). Hybrid receptors bind
IGF-2 with the same afﬁnity than IR-A homodimers, whereas they
bind IGF-1 with a lower afﬁnity (Blanquart et al., 2008). In addi-
tion, most cells not only co-express the two IR isoforms but also
the IGF-1R. Also these receptors have a high degree of homology
with the insulin receptor and, on the basis of the availability of
hemireceptors synthesized inside the cell, may randomly assem-
bly to form hybrid receptor, i.e., receptors formed by heterologous
hemireceptors of the IR isoforms and the IGF-1R (Belﬁore et al.,
2009).
Therefore, at least three heterotetramers (hybrids) are present
in most cells: IR-A/IR-B, IR-A/IGF-1R, and IR-B/IGF-1R. Oth-
ers hybrid receptors cannot be excluded considering the possible
isoforms of IGF-1R (Moxham et al., 1989). Studies on hybrid
receptors are scarce and incomplete due to the lack of adequate
methodologies (Belﬁore et al., 2009). Therefore, the metabolic
and/ormitogenic responses of target cells (bothnormal andmalig-
nant) may also depend on the type and proportion of the different
receptors that they express (Figure 1; Staiger et al., 2007; Shukla
et al., 2009). To evaluate the speciﬁc contribution of each receptor
to the effect of different ligands, the biological effects of insulin and
its analogs were studied in cells expressing only one IR isoform
(either A or B) or the IGF-1R (Sciacca et al., 2010; Sommerfeld
et al., 2010). In addition, a number of studies have evaluated
the proliferative effects of insulin analogs in different cancer cell
lines (Liefvendahl and Arnqvist, 2008; Mayer et al., 2008; Shukla
et al., 2009; Weinstein et al., 2009; Sommerfeld et al., 2010) and
an increased mitogenic effect of long-acting analogs, relative to
insulin, has been observed in some instances. In addition to being
a more general effect, the mitogenic effect of insulin may be a
problem in individuals with undiagnosed tumors, often present
at an early stage, particularly when long-acting analogs and high
doses are used, because cancer cells may be more responsive to
insulin because of their increased IR expression with prevalently
IR-A presence. Lately, retrospective epidemiologic studies have
been published to investigate in diabetic patients the relative risk
FIGURE 1 | Insulin receptors (IR-A and IR-B), IGF-1 receptor (IGF-1R),
and hybrid receptors (IR-A/IR-B, IGF-1R/IR-A, and IGF-1R/IR-B). Insulin
binds with high afﬁnity to IR-A, IR-B, and hybrid receptors IR-A/IR-B (black
arrow), whereas binds with low afﬁnity to IGF-1R (black dotted arrow). IGF-1
binds with high afﬁnity IGF-1R and hybrid receptors IGF-1R/IR-A and
IGF-1R/IR-B (red arrow), whereas it binds with low afﬁnity to IR-A, IR-B, and
hybrid receptors IR-A/IR-B (red dotted arrow). IGF-2 binds with high afﬁnity
to IR-A, IGF-1R, and hybrid receptors IR-A/IR-B and IGF-1R/IR-A (green
arrow). IR-A, IGF-1R, and hybrid receptors IR-A/IR-B and IGF-1R/IR-A
predominantly mediate mitogenic effects. IR-B mediates prevalently
metabolic effects.
for cancer incidence associated with the use of insulin and its
analogs and an increased risk of cancer has been reported for
glargine insulin by some studies (Colhoun, 2009; Currie et al.,
2009; Dejgaard et al., 2009; Hemkens et al., 2009; Jonasson et al.,
2009; Mannucci et al., 2010). These studies, however, have been
heavily criticized for both methodology and analysis (Pocock and
Smeeth, 2009; Johnson andGale, 2010). However an increased risk
of cancer associated with treatment with (high dose) of insulin
and long-acting insulin analogs cannot be excluded on the basis
of available clinical and experimental data.
INSULIN ANALOGS
Insulin analogs were developed in order to modify the phar-
macokinetics of injected insulin to better mimic its endogenous
secretion. By recombinant technology and site-directed mutage-
nesis, the insulin molecule has been modiﬁed to either prolong
or shorten its action time. According to pharmacokinetics, insulin
analogs can be divided into two major subgroups: short-acting
and long-acting. In diabetic patients the use of insulin analogs
has been shown to improve glycemic control without increasing
hypoglycemic events in respect to regular or neutral protamine
Hagedorn (NPH) insulin. Molecular modiﬁcations, however,may
change the analog interaction with the IR, in terms of residence
time of the ligand on the IR and post-receptor intracellular path-
way activation. Also the binding afﬁnity to IGF-1R, can be mod-
iﬁed. As a result an imbalance between metabolic and mitogenic
effects can occur (Figure 2).
Structure and characteristics of the insulin analogs are summa-
rized in Table 1.
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FIGURE 2 | Molecular mechanisms potentially involved in the mitogenic
effects of long-acting insulin analogs.Two main molecular mechanisms
have been hypothesized to inﬂuence the balance of metabolic and mitogenic
actions of long-acting insulin analogs: the longer residence of the ligand on
the IR and/or an increased binding afﬁnity of the insulin analog for IGF-1R may
predominantly activate the mitogenic signaling.
Table 1 | Structure and characteristics of insulin analogs approved for
clinical use.
Analog Structure Characteristics
Lispro Lys(B28)Pro(B29) Short-acting, rapidly absorbed
Aspart Asp(B28) Short-acting, rapidly absorbed
Glulisine Lys(B3)Glu(B29) Short-acting, rapidly absorbed
Glargine Gly(A21)Arg(B31)Arg(B32) Long-acting, smooth peak, low vari-
ability, injected as an acid solution
Detemir Lys(B29)(N-
tetradecanoyl)des(B30)
Long-acting, smooth peak, low vari-
ability, high afﬁnity for albumin
SHORT-ACTING INSULIN ANALOGS
– Insulin Lispro was the ﬁrst genetically engineered rapid-acting
insulin analog to become available for clinical use. Insulin lispro
(LysB28, ProB29 human insulin) has been produced by recombi-
nant DNA method. In insulin lispro molecule the B chain nat-
ural sequence of human insulin is reversed between proline at
position 28 and lysine at position 29. This amino acid sequence
alteration leads to a conformational shift in the C-terminus of
the B chain, reducing the insulin ability to self-associate in solu-
tion (Brems et al., 1992; Holleman and Hoekstra, 1997), thus
obtaining faster absorption and higher peak serum level after
injection.
– Insulin Aspart (AspB28) is a recombinant human insulin ana-
log obtained by changing insulin B chain proline at position
28 with the negatively charged aspartic acid. Pharmacokinetics
and pharmacodynamics properties of insulin aspart are similar
to those of insulin lispro (Plank et al., 2002).
– Insulin Glulisine (LysB3, GluB29) has been obtained by substi-
tuting the aspartic acid in position B3 with lysine and the lysine
in position B29 with glutamine. These changes in the analog
molecule reduce the rate of self-association when injected into
the subcutaneous tissue, thus providing immediate biological
availability (Becker, 2007).
After injection, the absorption proﬁle of short-acting analogs
reaches a peak that is approximately twice that of injected human
insulin and is reached in approximately one half of the time.
Binding afﬁnity for the insulin receptor of lispro insulin (Slieker
and Sundell, 1991), insulin aspart (Simpson and Spencer, 1999;
Kurtzhals et al., 2000), and glulisine (Hennige et al., 2005) is sim-
ilar to that of native insulin. Their duration of action is shorter
(approximately two times than native insulin; Howey et al., 1994;
Heinemann et al., 1998; Becker and Frick, 2008).
LONG-ACTING INSULIN ANALOGS
Insulin glargine
Insulin glargine (GlyA21, ArgB31, ArgB32 human insulin) has
been produced by recombinant DNA techniques, substituting the
asparagine at position 21 in the A chain with glycine and adding
two arginine residues to the B chain at positions 31 and 32.
Insulin glargine is soluble at acid pH but less soluble at neutral
pH, because its isoelectric point is at pH ∼6.4–6.6 (Bolli et al.,
1999). Insulin glargine is injected subcutaneously as an acid solu-
tion (pH 4.0) but in the neutral environment it precipitates and
forms in the subcutaneous tissue a depot from which insulin is
slowly released (Owens et al., 2000). The insulin receptor afﬁnity of
insulin glargine is similar to that of human insulin (Kurtzhals et al.,
2000; Sciacca et al., 2010; Sommerfeld et al., 2010). Its duration of
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action is approximately 20 h at physiological doses (Lepore et al.,
2000; Heise et al., 2002).
Insulin detemir
Insulindetemir [LysB29(N -tetradecanoyl)des(B30)human insulin]
is not a real insulin analog but should rather be considered
an insulin derivative because the B30 amino acid threonine is
removed and a 14-carbon myristoyl fatty-acid is acylated to lysine
at B29 (Markussen et al., 1996) obtaining a molecule that includes
an insulin analog and a fatty-acid chain. After subcutaneous injec-
tion, insulin detemir avidly binds to albumin through the fatty-
acid chain and this reversible binding to albumin (approximately
98% of the amount of insulin detemir injected) on one hand pro-
longs thedurationof detemir action andalso reduces the biological
availability of free insulin detemir.Althoughdetemir is 98%bound
to albumin, there is no evidence of detemir interaction with other
albumin-bound proteins or differences in the analog kinetics in
low albumin states (Kurtzhals et al., 1997). The insulin detemir
afﬁnity for the receptor, both in cultured and in vivo, is reduced
due to the interference of albumin binding (Markussen et al., 1996;
Sciacca et al., 2010). In clinical use, to obtain a similar biologic
effect on blood glucose, insulin detemir must be administered to
diabetic patients in the amount of 0.142mg of the analog per unit
instead of 0.036mg per unit as for human native insulin and the
other insulin analogs (3.9-fold higher detemir insulin molecule
number than human insulin or other analog molecule number
per injected unit).
IN VITRO MITOGENIC EFFECTS OF INSULIN ANALOGS
As already mentioned, molecular modiﬁcations present in insulin
analogs may change their afﬁnity for the IR and IGF-1R, their
intracellular signaling and their biological effects. One critical
item for approving the clinical use of insulin analogs has been the
assessment of their mitogenic effects (growth-promoting activity)
in benign and malignant cell lines in vitro.
INSULIN ANALOGS INTERACTION WITH INSULIN AND IGF-1
RECEPTORS
Studies on insulin (and its analogs) binding to each IR isoform
are difﬁcult because the large majority of cells express both IR
isoforms and no direct measurement of the IR isoform proteins
is available. By measuring the IR isoform transcript, cell models
that naturally express only one IR isoform have been identiﬁed
among malignant cells. More conveniently, engineered cell mod-
els have been constructed in non-transformed cells by expressing
either only the IR-A or the IR-B isoform by transfecting with an
expression vector containing the human cDNA of only one IR
isoform (Sciacca et al., 2010; Sommerfeld et al., 2010). These are
not perfect models because transfected receptors are often overex-
pressed and species speciﬁc native IR, even if at a very low level, are
present in the cells used. Therefore, different models and differ-
ent experimental procedures provided somewhat different results.
However, overall data indicate that short-acting insulin analogs
(aspart, lispro, and glulisine) bind to both IR isoforms with an
afﬁnity similar to that of native insulin or only slightly reduced
(Table 2). In contrast, long-acting analogs have a reduced afﬁn-
ity for both IR isoforms and this is more evident for detemir,
even when experimental conditions minimize albumin interfer-
ence (Markussen et al., 1996; Kurtzhals et al., 2000; Sciacca et al.,
2010; Sommerfeld et al., 2010).
Only few studies have measured the insulin analogs’ dissoci-
ation from the two IR isoforms, an important parameter since
insulin effects on target cells depend also from the ligand residency
time on the receptor. Data are scarce and, again,not fully compara-
ble because of the different experimental conditions. However, for
short-acting analogs the dissociation from the IR isoforms appears
Table 2 | Insulin and insulin analog binding affinity for the two IR isoforms.
Cell model Measurement Insulin Short-acting analogs Long-acting analogs
Aspart Lispro Glulisine Glargine Detemir
IR-A
R−/IR-A (1) EC50 (nmol/l) 0.40±0.10 0.60±0.15 0.43±0.15 0.61±0.03 0.93±0.17 0.90±0.26
CHO/IR-A (2) EC50 (nmol/l) 0.49±0.04 // // // 0.83±0.08 //
BHK/IR-A (3) % 100 92±6 84±6 // 86±3 18±2
IR-B
R−/IR-B (1) EC50 (nmol/l) 0.49±0.05 0.70±0.25 0.54±0.11 0.74±0.25 0.58±0.31 14.01±1.83
CHO/IR-B (2) EC50 (nmol/l) 0.57±0.02 // // // 1.10±0.12 //
Rat-1/IR-B (4) EC50 (nmol/l) ≈60 // // ≈70 // //
Pig (5) % 100 // // // // 46±5
(1) R−/IR-A: mouse embryo ﬁbroblasts KO for IGF-1R transfected with human IR-A (Sciacca et al., 2010).
(2) CHO/IR-A: hamster ovary cells transfected with human IR-A (Sommerfeld et al., 2010).
(3) BHK/IR-A: WGA puriﬁed receptors from baby hamster kidney cells transfected with human IR-A (Kurtzhals et al., 2000).
(1) R−/IR-B: mouse embryo ﬁbroblasts KO for IGF-1R transfected with human IR-B (Sciacca et al., 2010).
(2) CHO/IR-B: hamster ovary cells transfected with human IR-B (Sommerfeld et al., 2010).
(4) Rat-1/IR-B: rat ﬁbroblasts transfected with human IR-B (Hennige et al., 2005).
(5) Pig, unknown which IR isoform (Markussen et al., 1996).
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similar to that of native insulin while the long-acting analogs have
a slower dissociation rate (about 1.5–3 times longer) as indicated
by studies where both cell models or solubilized receptors were
used.
Data on IR isoform phosphorylation after exposure to insulin
analogs are not only rare but also extremely difﬁcult to compare
because of the different experimental conditions (i.e., cell types,
dose-response, time-course, etc.). However, when analogs were
compared in the same cell model, both short-acting and long-
acting insulin analogs activated IR isoforms’ phosphorylation in
a similar manner than human insulin (Sciacca et al., 2010; Som-
merfeld et al., 2010). In contrast to phosphorylation, differences
between insulin and insulin analogs were evident at downstream
post-receptor level. The results onAKT (amarker of themetabolic
insulin signaling pathway) and extracellular-signaling-regulated
kinase (ERK) phosphorylation (a marker of mitogenic insulin
signaling pathway) after cell exposure to short-acting analogs
indicated only subtle differences for either the amount or the
time-course of the AKT and the ERK activation. In contrast, more
marked differences relative to insulin were observed after receptor
stimulation with long-acting analogs. Via IR-A both glargine and
detemir activated AKT similarly to insulin and ERK more than
insulin. Via IR-B both analogs activated AKT less than insulin and
ERK similarly to insulin. In both cases the net result was that the
two long-acting analogs produced an ERK/AKT activation ratio
clearly shifted in favor of ERK (Sciacca et al., 2010).
At physiologic concentration insulin binding to the IGF-1R is
minimal or absent and themitogenic effects of insulin, once attrib-
uted to its interaction with the IGF-1R, are known to occur as an
intrinsic characteristic of the IR activation. However, a serious
concern with insulin analogs is whether the modiﬁed molecular
structure may cause an increased afﬁnity for the IGF-1R relative
to native insulin and, as a consequence, an increased mitogenic
effect.
The cancer risk associated with the IGF-1R expression and acti-
vation is well recognized (Furstenberger and Senn, 2002; LeRoith
and Roberts, 2003; Renehan et al., 2004; LeRoith andYakar, 2007).
The therapeutic concentrations of insulin are usually below the
range required for IGF-1R activation. However if the structure
modiﬁcation of the insulin analogs alters their binding afﬁnity
for IGF-1R (Bahr et al., 1997; Slieker et al., 1997; Kurtzhals et al.,
2000; Sciacca et al., 2010; Sommerfeld et al., 2010) their mitogenic
potential can be increased. Different cell models and different
experimental protocols were used to measure analog afﬁnity for
IGF-1R overcoming the difﬁculties due to the interference of the
cognate IR. Results were not always concordant.
Among short-acting analogs two out of three studies indicate
that lispro has a slightly higher afﬁnity for the IGF-1R in compari-
son to insulin (Table 3; Kurtzhals et al., 2000),whereas in the other
study aspart insulin was found to bind IGF-1R less than insulin
(Kurtzhals et al., 2000). In an engineered cell model expressing
only the human IGF-1R, the three short-acting analogs bound to
this receptor similarly to native insulin (Table 3; Sciacca et al.,
2010).
It is today demonstrated that the long-acting insulin analog
glargine binds to the IGF-1R with higher afﬁnity than insulin and
in some of those studies the increased mitogenic effect of glargine
has been attributed to its increased IGF-1R activation.After subcu-
taneous injection in patients, however, proteolytic degradation of
glargine produces two metabolically active metabolites, M1 and
M2 (Sommerfeld et al., 2010), which apparently have reduced
IGF-1R afﬁnity and reduced mitogenic potency relative to insulin
(Sommerfeld et al., 2010). The accurate quantiﬁcation of glargine
metabolites and their ability to stimulate IR isoforms and IGF-1R
require further clariﬁcation.
The other long-acting insulin analog, detemir, has been studied
much less than glargine. In one study the analog interaction with
IGF-1R was calculated to be very low, approximately on sixth that
of human insulin (Kurtzhals et al., 2000). But in a different model
(engineered cells overexpressing IGF-1R and experimental condi-
tions with very low albumin concentration) the two long-acting
insulin analogs (detemir and glargine) showed a very similar IGF-
1R binding afﬁnity, for both higher than human insulin (Sciacca
et al., 2010). In the same cell model detemir, however, was more
potent than glargine in causing IGF-1R phosphorylation (Sciacca
et al., 2010).
No data are available on insulin analogs’ interactions with
hybrid receptors and on their post-receptor signaling after hybrid
Table 3 | Insulin, IGF-1, and insulin analog binding affinity for the IGF-1R.
Cell model (IGF-1R) Measurement IGF-1 Insulin Short-acting analogs Long-acting analogs
Aspart Lispro Glulisine Glargine Detemir
R+/IGF-1R (1) EC50 (nmol/l) 2.23±0.23 >1,000 >1,000 >1,000 >1,000 ≈300 ≈300
3T3/IGF-1R (2) EC50 (nmol/l) 0.89±0.19 289±53.3 // // // 63.2±19.9 //
H9c2 (3) EC50 (nmol/l) // ≈500 // // // ≈350 //
HMEC P12 (4) EC50 (nmol/l) 0.42±0.02 326±23 // 74±2 // // //
BHK/IGF-1R (5) % // 100 81±9 156±16 // 641±51 16±1
(1) R+/IGF-1R: mouse embryo ﬁbroblasts KO for native IGF-1R and transfected with the human IGF-1R cDNA (Sciacca et al., 2010).
(2) 3T3/IGF-1R: mouse embryo ﬁbroblasts transfected with human IGF-1R (Sommerfeld et al., 2010).
(3) H9c2: rat heart muscle cell line (Bahr et al., 1997).
(4) HMEC P12: human mammary epithelial cells (Slieker et al., 1997).
(5) BHK/IGF-1R: WGA puriﬁed receptors from baby hamster kidney cells transfected with the human IGF-1R cDNA (Kurtzhals et al., 2000).
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receptors’ activation because of technical difﬁculties to carry out
the necessary experiments.
THE MITOGENIC EFFECTS OF INSULIN ANALOGS ON CANCER CELLS
The growth-promoting effect of insulin analogs has been manly
studied in malignant cell lines. When using malignant cell lines
for assessment of insulin activity, insulin effect on cell prolifera-
tionmust consider thatmalignant transformation per se affects the
cell growth rate via endogenous and exogenous mechanisms and
that a remarkable heterogeneity exists between different malig-
nant cell types. In addition to this limitation, the studies on the
mitogenic effects of insulin analogs in cancer cells, only few stud-
ies have compared the proliferative effect of all insulin analogs in
the same cell models. Moreover, the mitogenic effect of insulin
analogs has been usually evaluated at supraphysiological doses
(50–100 nM). Generally, short-acting insulin analogs stimulated
cancer cell proliferation in a similar manner than human insulin
(Kurtzhals et al., 2000; Mayer et al., 2008; Shukla et al., 2009;
Weinstein et al., 2009) while long-acting analogs stimulate pro-
liferation more than insulin. Although data are not homogeneous
and observations on the more recently introduced detemir are
scarce, in a variety of cell models both glargine and detemir often
show an increased mitogenic response. In particular, in human
osteosarcoma cells (Saos-2) that express IGF-1R more than IR,
insulin glargine was more potent than native insulin for stim-
ulating growth (Kurtzhals et al., 2000; Sommerfeld et al., 2010).
However when insulin glarginemetabolitesM1 andM2were eval-
uated in Saos-2 cells, their mitogenic effect was similar to that
of human insulin (Sommerfeld et al., 2010). When the effects of
human insulin, IGF-1, and long-acting insulin analogs glargine
and detemir were compared for the stimulation of proliferation in
colorectal (HCT-116),prostate (PC-3), and breast (MCF-7) cancer
cells, both long-acting analogs stimulated proliferation more than
insulin in all three cell lines, but always less than IGF-1 (Weinstein
et al., 2009). Other studies found an increased proliferation of
MCF-7 cells induced by glargine (Mayer et al., 2008; Shukla et al.,
2009) and that insulin glargine strongly activated the IGF-1R and
the mitogen activated protein (MAP) kinase pathway in MCF-7
cells. The predominant role of IGF-1R in mediating this mito-
genic effect was suggested by the observation that the proliferative
response to insulin glargine was reduced (and equipotent to that
of human insulin) in IGF-1R-knockoutMCF-7 cells (Shukla et al.,
2009). In these cells IR knockdown did not reduce the ability of
insulin glargine to activate phosphoinositide 3-kinase (PI3K) and
MAPK pathways, in contrast IGF-1R knockdown cognate cells.
These results may also been explained by the fact that the studied
cells have an IGF-1R/IR ratio greater than 1, suggesting a prevalent
role of IGF-1R in mediating the proliferative effect.
The interference of themodel and of the procedure heterogene-
ity is conﬁrmed by the study of insulin glargine on cell growth in
the breast cancer MCF-7 and SKBR-3 cells and in the osteosar-
coma Saos-2 cells. No signiﬁcant differences were found between
glargine and human insulin on DNA synthesis, although glargine
was slightly more potent than insulin (Liefvendahl and Arnqvist,
2008). Table 4 summarizes the mitogenic effect of insulin analogs
in different cancer cells as observed in different studies. The
results are expressed as percentage differences in respect to insulin
considered as 100%. In addition to variability in the cell model
used, also differences in the ligand concentrations studiedmust be
noted.
An important issue concerns the carcinogenic effect of insulin
analogs. Cancer initiation (carcinogenesis) indicates the process of
malignant transformation of normal cells. Data on this issue are
rare. Recently, in non-transformedmouse ﬁbroblasts overexpress-
ing IR-A or IR-B or IGF-1R, neither short-acting nor long-acting
insulin analogs stimulated anchorage-independent cell growth (a
transformation marker; Sciacca et al., 2010). However, in a previ-
ous study in 3T3 ﬁbroblasts overexpressing the IR, insulin depen-
dent formation of colony was observed (Giorgino et al., 1991).
Moreover, the increased mitogenic activity elicited by insulin and
Table 4 | In vitro mitogenic effect of insulin analog in cancer cells.
Cancer cell line Insulin Short-acting analogs Long-acting analogs
Aspart Lispro Glulisine Glargine Detemir
Saos-2 (1) 100 58 66 // 783 ≈11*
MCF-7 (2) 100 100 100 86 133 112
T47D (3) 100 100 100 // 100 118
MCF-7 (4) 100 100 100 // 140 117
HCT-116 (5) 100 // 108 // 122 117
PC-3 (6) 100 // // // 116 114
MCF-7 (7) 100 // // // 114 106
(1) Saos-2: human osteosarcoma cells. *Estimated potency (Kurtzhals et al., 2000).
(2) MCF-7: human breast cancer cells (Mayer et al., 2008).
(3) T47D: human breast cancer cells (Mayer et al., 2008).
(4) MCF-7: human breast cancer cells (Shukla et al., 2009).
(5) HCT-116: human colorectal cells (Weinstein et al., 2009).
(6) PC-3: human prostate cancer (Weinstein et al., 2009).
(7) MCF-7: human breast cancer cells (Weinstein et al., 2009).
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its analogs might, per se, increase the risk of errors in DNA
duplication and, therefore, cancer initiation.
IN VIVO STUDIES OF INSULIN ANALOGS AND CANCER
Recent retrospective observational studies using different diabetes
registries have published results on cancer association with the
use of insulin analogs in diabetic patients (Colhoun, 2009; Currie
et al., 2009; Dejgaard et al., 2009; Hemkens et al., 2009; Jonasson
et al., 2009). In these studies confounding factors and method-
ological ﬂaws render the interpretation of results questionable and
controversial.
First, in a retrospective cohort study of more than 127,000
patients treated in Germany with either human insulin, lispro,
aspart,or insulin glargine for amean follow-up timeof 1.63 years, a
dose-dependent association was found between all insulin analogs
and cancer incidence (Hemkens et al., 2009). After adjusting for
the administered dose, only glargine was related to an increased
cancer risk compared to human insulin (HR 1.31 for 50 IU daily
dose, p< 0.0001). As occurs with all retrospective cohort studies,
patients were not randomized to treatment groups and, despite
corrections for available confounders, several potentially rele-
vant factors, such as body mass index, duration of diabetes, and
smoking habit were not available. Moreover, the follow-up time
(1.6 years) was short.
At the same time, on the journal Editor request, data from
two additional retrospective observational studies, conducted in
Sweden and Scotland, were published in the same journal.
In the Swedish cohort almost 115,000 patients treated with
insulin were examined (Jonasson et al., 2009). The risk of devel-
oping breast cancer among women receiving insulin glargine
monotherapy was signiﬁcantly higher (RR 1.99, 95% CI, 1.31–
3.03) than among those using other insulin types. In this study
neither randomization nor correction for dose was possible and
the risk of developing other forms of cancer was not increased
with insulin glargine.
In the Scottish study the national registry data from almost
50,000 insulin treated patients were evaluated (Colhoun, 2009). A
small subset (N = 447) of patients receiving only insulin glargine
was found to have a higher risk of cancer than patients receiving
other insulins (RR 1.55, 95% CI, 1.01–2.37), with a signiﬁcantly
increased risk of breast cancer. The authors explain this result as a
possible bias because of the small number of events.
In the same year another retrospective cohort of almost 63,000
patients treated in the United Kingdom with insulin or oral hypo-
glycemic agents by general practitioners was published (Currie
et al., 2009). No signiﬁcant difference in cancer risk was detected
among users of insulin analogs compared with users of human
insulin.
Finally in a retrospective, case-control study of insulin treated
diabetic patients, cases with incident cancer were associated with a
higher dose of insulin glargine (Mannucci et al., 2010). In contrast,
no association between increased cancer incidence and insulin
dose was found for human insulin or other insulin analogs.
Only onemeta-analysis of theNovoNordisk database of clinical
trials has been published on the other long-acting analog detemir
(Dejgaard et al., 2009). This meta-analysis was performed in a
cohort of 8,693 patients. Patients treated with insulin detemir had
a similar occurrence of cancer comparedwith patients treatedwith
NPH insulin or insulin glargine. Also this study, as the ones previ-
ouslymentioned,has a series of limitations including study design,
lack of randomization, measured end-point procedures, and, in
addition, the small number of patients and the short follow-up
time (52weeks).
Although observational studies can usefully detect unexpected
drug effects, they may also favor biased conclusions. The problem
is that clinical decisions determining each patient’s treatment are
not random, people are prescribed different therapies for health-
related reasons. Health outcomes, therefore, might differ between
people taking different therapies even if the therapies themselves
have no such effect. Despite adjustment for confounders, residual
selectionbiasmight distort true differences between treatments.As
patients’ diabetes progresses, their mortality risk increases. More-
over, poor glycemic control might prompt the introduction of
insulin, creating systematic differences between patients receiv-
ing oral antidiabetic drugs or insulin and adding confounding
factors related not only to drug differences but also to patient
metabolic and general situationwhen therapywas selected.Higher
doses of insulin required by the poor metabolic control will be
linked to higher mortality due to other reasons, an artifact of
treatment change as disease advances, rather than actual treat-
ment effects. Another issue is reverse causality: cancer often has a
long period between biological onset and clinical diagnosis. Dur-
ing the subclinical phase, insulin requirements might be affected
by the undetected cancer, and lead to treatment changes. To the
unwaryobserver, this treatment change can appear as favoring can-
cer, when vice versa it is cancer that produces treatment change
(Pocock and Smeeth, 2009).
As already mentioned, therefore, the available clinical evidence
can neither demonstrate nor exclude an increased risk of can-
cer in diabetic patients treated with insulin analogs. The evidence
reported for glargine is not only weak but also strongly criticizable
and controversial. No independent study is available for detemir.
The concern, therefore, cannot be excluded also because the pos-
sibility of an increased mitogenic effect is supported by numerous
in vitro studies.
CONCLUSION
The question of an increased mitogenic effect, in vitro and in vivo,
of modiﬁed insulin analogs remains open.
In vitro results indicate an increased relative mitogenic potency
of long-acting insulin analogs relative to insulin. Evidence strength
is limited by the use of malignant cells, of supraphysiological con-
centrations of ligands and also by much possible interference in
the experimental procedures. Even if an increasedmitogenic activ-
ity of these analogs is admitted in vitro, this does not necessarily
represent what happens when insulin analogs are administered to
patients (Kurtzhals et al., 2000; Mayer et al., 2008; Shukla et al.,
2009; Weinstein et al., 2009; Sciacca et al., 2010; Sommerfeld
et al., 2010). In vivo injected analog distribution, metabolism, and
clearance may be very different. For instance, glargine is trans-
formed into M1 and M2 metabolites (Sommerfeld et al., 2010)
and detemir is strongly bound to albumin.Moreover, different tis-
sues will respond differently on the basis of the quantity and the
quality of the receptors expressed. Retrospective epidemiological
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studies on the risk of cancer in patients treatedwith insulin analogs
are scientiﬁcally weak and controversial. Prospective trials are not
available, difﬁcult to design because of the heterogeneity of the
diabetic population and the number of confounding factors, and
very unlikely to be performed in the next future. Since an increased
risk of cancer associated with insulin analogs therapy cannot be
excluded, strict surveillance and studies with new approaches and
with long-term follow up are needed.
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